Head-to-head · WeighScore
Nurx vs Ondra Health
The verdict
Ondra Health takes it — 86.8/100 to 66.2/100.
Ondra Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Lowest semaglutide sticker on the board ($93) paired with some brand-name access and LegitScript verification.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Nurx | Ondra Health |
|---|---|---|
| WeighScore | 66.2/100 | 86.8/100 |
| Grade | C | B |
| Scorecard rank | #199 | #12 |
| Semaglutide | $179/mo (starting dose, compounded) | $93/mo |
| Tirzepatide | $179/mo (starting dose, compounded) | $166/mo |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #199 · C
Strengths
- Both semaglutide and tirzepatide available
- Compounded GLP-1 access
Where it loses points
- Limited public information on program details
Graded #12 · B
Strengths
- Lowest listed semaglutide price ($93/mo)
- Some brand-name access
- LegitScript-verified, all 50 states
Where it loses points
- Tirzepatide steps up to $166/mo
- Labs/monitoring detail not published
- Compounded-first
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.